

November 20, 2020

David-Alexandre Gros
Chief Executive Officer
Novus Therapeutics, Inc.
19900 MacArthur Blvd., Suite 550
Irvine, CA 92612

Inc.

Statement on Schedule 14A

2020

Re: Novus Therapeutics,

Preliminary Proxy

Filed October 23,

File No. 001-36620

Dear Dr. Gros:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance

Office of Life Sciences

cc:

Ryan A. Murr